Voyager Therapeutics, Inc.
VYGR
$3.47
-$0.06-1.70%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -74.51% | -16.73% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -74.51% | -16.73% | |||
| Cost of Revenue | 17.66% | -12.22% | |||
| Gross Profit | -422.18% | -15.14% | |||
| SG&A Expenses | 10.11% | -19.54% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 16.06% | -13.89% | |||
| Operating Income | -177.93% | 8.29% | |||
| Income Before Tax | -276.66% | 11.03% | |||
| Income Tax Expenses | 1,258.14% | 79.17% | |||
| Earnings from Continuing Operations | -281.32% | 10.82% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -281.32% | 10.82% | |||
| EBIT | -177.93% | 8.29% | |||
| EBITDA | -194.81% | 7.23% | |||
| EPS Basic | -280.61% | 11.04% | |||
| Normalized Basic EPS | -276.03% | 11.23% | |||
| EPS Diluted | -273.63% | 11.11% | |||
| Normalized Diluted EPS | -276.03% | 11.23% | |||
| Average Basic Shares Outstanding | 0.21% | 0.22% | |||
| Average Diluted Shares Outstanding | 0.21% | 0.22% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||